Subtype
Colorectal Carcinoma with Genetic Abnormalities
CI-CAN-00007526Explore in graph →
11 active trials3 approved drugs
- NCIt
- C227216
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007526Explore in graph →
Clinical trials
31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04301557 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06262581 | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT05815290 |
| Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer |
| unknown |
| Phase 2 |
| 50 |
| Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER |
| 1 |
| Apr 18, 2023 |
| clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2024source: clinicaltrials